Dara-BCD for Rare MGRS

Exclusion Criteria

• •1. Prior therapy for MGRS, with the exception of equal or less than 160 mg dexamethasone (or equivalent corticosteroid)
• •2. Fulfill with the criteria of active multiple myeloma or active lymphoplasmacytic lymphoma.
• •3. Presence of other tumors which is/are in advanced malignant stage and has/have systemic metastasis;
• •4. Severe or persistent infection that cannot be effectively controlled;
• •5. Presence of severe autoimmune diseases or immunodeficiency disease;
• •6. Patients with active hepatitis B or hepatitis C (\[HBVDNA+\] or \[HCVRNA+\]); Patients with HIV infection or syphilis infection;
• •7. Any situations that the researchers believe will increase the risks for the subject or affect the results of the study.